$Kala制药(KALA)$ KALA Kala Pharmaceuticals risk/reward 'highly favorable,' says JPMorgan

JPMorgan analyst Christopher Neyor reiterates an Overweight rating on Kala Pharmaceuticals with a $17 price target after meeting with management. The analyst sees a "highly favorable risk/reward" for Kala, underpinned by Eysuvis, the company's lead product. The early stage launch has a "significant" market opportunity in dry eye, Neyor tells investors in a research note. With Kala shares trading at a $450M market capitalization, the shares offer an "attractive entry opportunity and valuation case," says the analyst. 

市场还认为该药是和普通激素滴眼液雷同,大错特错,静待它幡然醒悟一飞冲天

 $阿米瑞斯(AMRS)$ $Affimed(AFMD)$
雪球转发:0回复:0喜欢:0